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In Vivo Human Transfer of Topical Bioactive Drug
between Individuals: Estradiol
Ronald C. Wester1,2, Xiaoying Hui1,2 and Howard I. Maibach1,2
This study determined the in vivo human bioavailability of topical estradiol, and the transfer of drug between
dosed subject and naive recipient. In vivo bioavailability was determined in human volunteers by 14C urinary
excretion following topical [14C]-estradiol (0.06%) dose administration and were adjusted by intravenous human
excretion amounts to give absolute bioavailability amounts. Drug transfer was determined by volunteer skin
contact/rubbing for 15 minutes, 1 hour after topical dosing. [14C]-estradiol bioavailability as percent dose
absorbed (n¼ 6) was 7.574.1 from protected dose site, 8.276.3 from non-protected dose site, 6.677.6 from
dosed volunteers subjected to skin contact/rub and 4.373.8 from non-dosed volunteers subjected to skin
contact/rub. Between these small groups, the values were not statistically different. Under experimental
conditions, a measurable dose of radioactive 17b-estradiol dose was delivered to naive recipient volunteers
through skin contact/rub with other volunteers previously topically dosed. Any residual topical bioactive
chemical which resides on the open skin surface can transfer by skin contact to another individual. It is
important for prescribing physicians and patients to understand that clinically significant transfer of topical
bioactive drugs can occur. This may be particularly important for substances which may produce inadvertent
effects.
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INTRODUCTION
Topical chemical application used to be thought of as that for
local drug dermatological treatment, or perhaps as a cosmetic
application. Now bioactive drugs are topically administered
for systemic treatment such as hormonal replacement
estrogen therapy (Jewelewicz, 1997). Zondek (1938) reported
that if a hormone (oestrone) ointment or hormone oil is
rubbed into the shaven skin of the back of a castrated mouse
the animal goes into oestrus. He also observed that the
topical dose required seven times as much hormone as with
subcutaneous injection. The 7 difference is topical dose
not absorbed through the skin. Feldmann and Maibach
(1969) showed estradiol human percutaneous absorption to
be 10.6% for 24 hours dose application. The remaining dose
was washed off or lost.
Studies in percutaneous absorption have shown that a
portion of the topical chemical, generally a few percent of
the applied dose, became systemically available. This few
percent dose absorbed was sufficient for certain bioactive
drugs and led to transdermal drug delivery for systemic
application. During the topical drug application period,
generally 24 hours, mass balance has shown that the majority
of the topically applied dose was still on the skin (Wester and
Maibach, 1992). In essence, an excess of drug is on the skin
through the complete topical dosing period.
Johnson et al. (1983) showed that in 50 hospitalized
patients given tetracycline ointments, creams, lotions, and
tinctures containing a fluorescent marker, the topically
applied medications did not remain confined to sites of
initial application. Yerasi et al. (1997) report an unusual
case where a man died of fentanyl poisoning, yet it was his
wife who had the fentanyl patches. Wolf et al. (1997)
reported childhood poisoning involving transdermal nicotine
patches. Lu and Fenske (1999) report dermal transfer of
pesticide residues from residential surfaces. Franklin and
Geffner (2003) reported a case of pronounced virilization of
a 2-year-old boy from a topical testosterone cream being
used by his father. Vihtama¨ki et al. (2004) showed skin conta-
mination by estradiol gel to be a remarkable source of error in
plasma estradiol measurements. Topical estradiol and testo-
sterone preparations are available as well as other topical
bioactive preparations. This study examines 17b-estradiol
human skin in vivo percutaneous absorption, including skin
transfer between individuals.
RESULTS
Table 1 summarizes the clinical results. Urinary 14C excretion
was 3.972.1, 4.273.2, 3.474.0, and 2.272.0% applied
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dose for clinical Groups A–D, respectively. These urinary
excretion calculated relative to an intravenous dose
(Feldmann and Maibach, 1969) gave topical bioavailability
as percent doses absorbed of 7.574.1, 8.276.3, 6.677.6,
and 4.373.8 for A–D, respectively. There were no statistical
differences between these groups. The 14C concentration
in the urine samples decreased with half-lives of 28.479.1,
30.8712.0, 29.374.5, and 33.6713.1 hours, respectively,
for Groups A–D. There were no statistical differences
between these small groups.
After the 24-hour dosing period, the dosed skin site was
washed with soap and water, and the skin was tape stripped
on day 7 for residual chemical. The protective cover or sleeve
was also analyzed for residual chemical. Table 2 shows that
73–74% applied dose was recovered in the wash from Group
A after the 24-hour dose period. There was no residual
chemical in day 7 tape strips. Group B wash recovery was
27–29%, and 14–24% transferred to the covering sleeve.
There was no residual dose in the tape strips. Group C wash
recovery was 36%, and 13% was recovered from the sleeve.
Group D wash recovery was 2.3 and 4.1% recovered from
the sleeve. Tape strips were not carried out on Groups C and
D because the dosing area could not be defined after the skin
rub/contact. Dose accountability for the groups are listed in
Table 1. The results show the majority of the topical dose
(Groups A and B) resides on the surface of the skin during the
24-hour dosing period. The dose is available for skin transfer
(Group C) and that skin-transferred dose will be absorbed by
the recipient person (Group D).
DISCUSSION
Topically applied chemicals reside on the skin for an extended
dosing period, and these chemicals can transfer through skin
contact with another naive person. This is probably of no
consequence for inert chemicals; however, potent topical
bioactive chemicals have become available. An example
given previously was of topical testosterone on a father which
this study has shown could transfer by contact to his son. The
testosterone cream was applied without attention to hand
washing after application or the possibility of contact trans-
mission to other family members. This began a few months
after his son’s birth (Franklin and Geffner, 2003). Different
from testosterone which may induce inadvertent effects in
immature and female individuals, no relevant risk scenario is
currently known from possible transfer of 17b-estradiol.
Our study, using single defined doses of labeled estradiol
(about 0.1 mg) and demonstrating absorption rates o10%,
was unlikely to produce systemic biological effects in this
case. Topical drugs intended for systemic delivery are
routinely used over an extended period of time. Our Group
A results show that 73–74% protected estradiol dose was still
on the skin, and Group B showed 27–29% dose still on the
unprotected skin and 14–24% on the clothing (sleeve),
probably all still available for absorption. Since the total
bioavailability was 7.5% for Group A and 8.2% for Group B,
a large portion of active substance is still available for
transfer/absorption. This study does not answer the question
of how long residual topical drug would be available for
Table 1. Clinical group1
Mean percent dose7SD (n = 6)
A B C D
Urinary 14C
excretion
3.972.1 4.273.2 3.474.0 2.272.0
Topical
bioavailability2,3
7.574.1 8.276.3 6.677.6 4.373.8
T1/2 renal
excretion (hours)
28.479.1 30.8712.0 29.374.5 33.6713.1
Dose
accountability4
82.075.3 56.9711.0 56.977.1 10.877.9
1A=dose site protected with non-occlusive cover (n=6).
B=Dose site not protected (n=6).
C=skin site dosed, then rubbed on volunteer in group D (n=6).
D=naı¨ve recipient of skin contract/rub (n=6).
2Topical bioavailability=urinary excretion (topical dose)/urinary excretion
(i.v. dose)100; 51.6% dose excreted after single i.v. dose human
(Jewelewicz, 1997).
3No statistical difference (P40.05).
4Please note that mass balance is higher where topical dose was better
controlled.
Table 2. Clinical group – treatment forearm
Mean percent dose7SD (n = 6)
A B C D1
Wash Left 73.0710.0 27.274.0 36.1714.4 2.372.0
24 hours Right 74.076.1 29.074.0 — —
Cover2 Left 0.976.12 24.2714.43 12.976.63 4.173.63
or
Sleeve3 Right 1.271.62 13.773.83 — —
Tape strip Left 0.0270.01 0.0570.07 — —
Day 7 Right 0.0270.02 0.0370.03 — —
1The percent recovery in Group D is based on the dose applied to Group C.
2Cover is non-occlusive/non-skin touching cover over the dosed site.
3Sleeve is disposable cover placed over the arm to stop the spread of radioactivity to the volunteer’s clothing and environment.
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transfer relative to time on skin, formulation changes, or
effect of routine skin washing.
Topical bioavailability using cumulative urinary recovery of
estradiol in this study was 7.574.1 and 8.276.3% doses for
Groups A and B. This compares favorably with the published
in vivo estradiol percutaneous absorption of 10.674.9% doses
(Feldmann and Maibach, 1969). This study and the report by
Franklin and Geffner (2003) document transfer of estradiol and
testosterone. During discussions on sport’s doping (BALCO,
Olympics), the ‘‘cream’’ (testosterone) gets mentioned as a
contributing factor. There is the report cited earlier of
suspected fentanyl transfer (Yerasi et al., 1997). This transfer
potential will apply to any bioactive topical chemical, and this
should not be restricted to drugs. Hazardous environmental
chemicals (pesticides, herbicides, pollutants) can topically
settle on one individual and be transferred to another person.
This study shows only the one rub/contact sequence for
one time period after dosing for one formulation. In the real
world, skin contact will occur under a variety of conditions,
and each variable will contribute to overall chemical skin
transfer. More data are thus warranted. However, the
potential for skin transfer of topical bioactive chemicals has
been shown in vivo in human volunteers and an awareness of
this effect should be heeded.
MATERIALS AND METHODS
Dose formulation
[14C]-estradiol, [4-14C]-NEC-127 estradiol with a specific activity of
54.1 mCi/mmol was obtained from DuPont NEN (lot number
3188–151SP), and was kept at 0–41C until used. Radiochemical purity
of 98.5% was determined by HPLC and thin layer chromatography.
The formulation was a gel (oestrogel) prepared according to the
manufacturer. An appropriate amount of [14C]-estradiol was
incorporated to be a 0.06% (w/w) dose formulation containing
5 mg [14C]-estradiol radioactivity per 8.5 g of gel (131 mCi/g). The
radioactive estradiol was incorporated into the gel. Triplicate
aliquots were assayed to determine uniformity of formulation. Use
of radioactivity was necessary to distinguish between that estradiol
[14C] which was absorbed through the skin and that estradiol which
is a natural constituent of the human body.
Study design
Group A was to determine topical absorption of [14C]-estradiol
under a protective condition during a 24-hour exposure period. The
protective non-occlusive cover placed on the dosed area and kept
for 24 hours was to protect the dosed site and exclude drug loss.
After 24 hours, the dosed site was washed with soap and water and
the washing sample was retained for 14C assay. The cover was
assayed for possible residual chemical.
Group B was to determine topical absorption on [14C]-estradiol
under normal use conditions, which had no protective device during
the 24-hour exposure period.
Group C was to determine how much [14C]-estradiol transferred
after contact with Group D. At 1 hour after topical dose, the dose
area was rubbed and contacted by a Group D volunteer who did not
receive any dose.
To prevent [14C]-estradiol transferring from the dosed site skin
to other skin area via contaminated clothes, a Tyvek paper sleeve
(Lab Safety Supply) was placed on each dosed forearm and kept in
place for the 24-hour dosing period for Groups B–D volunteers. After
24 hours, the dosed site was washed with soap and water, and the
washings retained for 14C assay. The sleeve was assayed for possible
residual chemical.
The experimental design and performance was followed the
Declaration of Helsinki Principles (Ethical Principles for Medical
Research Involving Human Subjects, see: www.wma.net) and
approved by the Committee on Human Research at the University
of California, San Francisco. Human volunteers were recruited from
the University of California, San Francisco and surrounding San
Francisco Bay Area community. Each volunteer signed a Consent
Form before the study. Eighteen healthy postmenopausal women
aged from 42 to 78 years were selected for Groups A–C. Six normal,
healthy men or women aged from 29 to 76 years were selected from
Group D. Each group consisted of six volunteers.
Dosing procedure
Group A. A 50 cm2 area (3.5 14.3 cm2) was marked on the left
and right ventral forearms of each volunteer. The marked areas
received a single topical application on each forearm of total 0.17 g
(22mCi) [14C]-estradiol gel formulation delivered with a 0.1 ml
Teflon-coated syringe (Hamilton Company, Reno, NV). The delivered
dose was quantitated by weighing the microsyringe before and after
dosing. This was carried out for all dosings. After topical applications,
a non-occlusive solid plastic cover was secured over each dosed area
of Group A volunteers and kept in place by tape for 24 hours. The
cover was made by cutting a plastic cylinder (20 cm length 5 cm
diameter) in half lengthwise, and drilling three 1 cm diameter holes in
the surface. This allowed free movement of air from its two open
holes on the top. The volunteers were requested not to touch or wash
the dosed area for 24 hours (this was asked of all groups).
Group B. A 50 cm2 area (3.5 14.3 cm2) was marked on the left
and right ventral forearm of each volunteer. The marked areas
received a single topical application in each forearm of total 0.17 g
(22 mCi) [14C]-estradiol gel formation delivered with a 0.1 ml Teflon-
coated syringe (Hamilton Company, Reno, NV). After dosing, the
dosed area was allowed to air dry for 1 hour after topical application.
After 1 hour, a Tyvek paper sleeve was placed on each dosed
forearm for 24 hours.
Group C. A 100 cm2 area (5.0 20 cm2) was marked on the left
ventral forearm of Group C volunteers. The marked area received a
single topical application of 0.16 g (22 mCi) [14C]-estradiol gel
formulation delivered with a 0.25 ml Teflon-coated syringe (Hamil-
ton Company, Reno, NV).
After topical application, the dosed area was allowed to air dry
for 1 hour, then rub and contact the ventral forearm (containing drug)
on the ventral forearm of Group D volunteers for 15 minutes. After
rubbing, the dosed forearm of Group C volunteers was placed in a
sleeve for 24 hours. The volunteers were requested not to touch or
wash the dosed area for 24 hours.
Group D. A ventral forearm of Group D volunteers was in contact
with the ventral forearm (containing drug) of Group C volunteers.
Skin contact consisted of rubbing five times up and down in one
direction (parallel to the axis of the arm), then close contact of skin
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surfaces for 15 minutes, then rubbing five times up and down in the
other direction. After rubbing, the contacted forearm of Group D was
placed in a sleeve for 24 hours.
Skin washing and analysis
At 20 hours after dosing, the cover or sleeve was removed and
each dosed site was washed using cotton balls (Sherwood Medical,
St Louis, MO), Ivory liquid soap (Proctor & Gamble, Cincinnati, OH)
and water. The water washing procedure was as follows:
(1) 50% Ivory soap solution (v/v).
(2) Distilled deionized water.
(3) 50% Ivory soap solution (v/v).
(4) Distilled deionized water.
(5) Distilled deionized water.
Each skin dosed area of Groups A–C volunteers was washed five
times. The area outside of the dosed skin on the ventral forearm
(called ‘‘non-dosed skin site’’) of Group C was also washed. Since
the whole skin area on the ventral forearm of Group D volunteers
was considered to receive the topical formulation after rubbing, it
was divided into two parts, the middle-upper and middle-lower of
the ventral forearm. Each part was washed five times using the
washing procedure. Individual cotton balls were placed in a
borosilicate glass vial containing 5.0 ml of methanol overnight and
then 10.0 ml scintillation cocktail was added. Appropriate dilutions
were made based on the radioactivity. Radioactivity in these samples
was analyzed by liquid scintillation counting to quantify the amount
of [14C]-estradiol removed from the application site. The cover was
also washed five times using the above procedure. The cotton balls
were individually placed in a borosilicate glass vial with 10.0 ml
scintillation cocktail. Radioactivity of these samples was counted
using the liquid scintillation counting.
Skin tape stripping and analysis
The tape stripping on Groups A and B was carried out 168 hours after
skin washing to analyze the residual dose. The dosed skin site was
stripped with Scotchs cellophane tape 5912 clear (3 M Commercial
Supply Division, St Paul, MN) 10 times. These tapes were then
individually placed in borosilicate glass vials with 5 ml of methanol
overnight, then 10 ml of scintillation cocktail was added, and
subsequently assayed for radioactivity by liquid scintillation count-
ing. Tape stripping was not carried out on Groups C and D because
the skin rubbing sequence changed the original dosing area.
Radioactivity of sleeve
The sleeve was cut into 20 pieces and individually placed in
borosilicate glass vials with 5 ml of methanol overnight, then 10 ml
of scintillation cocktail was added, and subsequently assayed for
radioactivity by liquid scintillation counting.
Urine sample collection and analysis
Urine samples were collected 0–24, 24–48, 48–72, 72–96, 96–120,
120–144, and 144–168 hours after dosing. The volume of urine
sample was measured and aliquots of urine sample (approximately
20 ml) were kept. Duplicate aliquots of 1.0 ml were used to
determine radioactivity. Estradiol topical bioavailability was deter-
mined by urinary 14C excretion and calculated relative to an
estradiol human intravenous dose (Feldmann and Maibach, 1969) to
determine absolute bioavailability.
Radioactivity assay
All radioactivity measurements were conducted using a Model 1500
Liquid Scintillation Counter (Packard Instruments, Downers Grove, IL).
The counter was audited for accuracy using sealed samples of
quenched and unquenched standards as detailed by the instrument
manual. Background control and test samples were counted in
duplicate where possible for 3 or 5 minutes each. Weighed aliquots or
urine, skin wash, tape strip, sleeve, and cover wash samples, skin,
receptor fluid were mixed directly with Universal Scintillation Cocktail
(ICN Biomedicals, Costa Mesa, CA) and analyzed for radioactivity.
Statistical analysis and topical bioavailability
Statistical analysis (t-test, one way analysis of variance) was carried
out using SIGMASTAT (SPSS Inc., Chicago, IL). Topical bioavail-
ability was calculated as urinary excretion (topical dose)/urinary
excretion (i.v. dose) 100. The data of urinary excretion following a
single i.v. dose, 51.6% dose excretion, was cited from Feldmann and
Maibach (1969) (Jewelewicz, 1997).
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